Baird analyst Brian Skorney raised the firm’s price target on Regeneron to $756 from $670 and keeps a Neutral rating on the shares. The analyst said the target increase was due t the continued strength of Dupixent and likely positive regulatory developments for 8mg aflibercept,
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Piper ups Regeneron price target to $800, says Q4 report ‘good enough’
- Regeneron Posts Q4 Beat; Shares Rise
- Regeneron announces new $3B share repurchase program
- Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
- Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03